Authors
Jiaqi Duan, Haoyue Zheng, Yongmin Xie, Lingzhi Xu, Yuanyi Zhang, Liguo Li, Pengyuan Zheng, Gui Yang, Pingchang Yang
Published in
Journal of advanced research. Nov 09, 2026. Epub Nov 09, 2026.
Abstract
Severe asthma is driven by uncharacterized Type 2-independent pathways, with 30-50% biologic non-response and no approved disease-modifying therapies for airway remodeling. The histone demethylase KDM4B and inflammatory mediator pentraxin 3 (PTX3) link to fibrotic lung disease, but their reciprocal regulatory circuit in dendritic cell (DC) senescence and severe asthma pathogenesis remain undefined. We previously reported unidirectional KDM4B-dependent PTX3 upregulation; here we define a fully validated bidirectional KDM4B-PTX3 positive feedback loop that sustains cDC2 senescence.
To investigate if a bidirectional epigenetically regulated KDM4B-PTX3 positive feedback loop in CD1c⁺ cDC2 senescence is a conserved Type 2-independent pathway driving severe asthma, and a viable therapeutic target and predictive biomarker.
In a discovery cohort (n = 226), plasma PTX3 was quantified and linked to outcomes. scRNA-seq mapped its cellular origin, while ChIP/ATAC-seq, in vitro assays, and HDM/PM2.5 mouse models delineated KDM4B-PTX3-driven DC senescence. A reverse PTX3 → KDM4B feedback loop was validated via recombinant stimulation, neutralization, and NF-κB inhibition. Inhaled KDM4B inhibitor QC6352 was evaluated for efficacy, with full formulation specs, lung/plasma PK, isoform selectivity, and extended 4-week post-treatment toxicology. A 5-gene PTX3-senescence signature was developed and validated in fully independent cohorts, with performance assessed by DeLong AUC, calibration, and decision curve analysis (DCA).
Plasma PTX3 was elevated in severe asthma, correlating with impaired lung function and exacerbations; CD1c⁺ cDC2 were the primary source. DC-specific Ptx3 knockout murine experiments confirm lung cDC2 drive ∼61% of circulating plasma PTX3 levels during chronic airway inflammation, resolving ambiguity regarding systemic PTX3's cellular origin. KDM4B epigenetically regulated PTX3 via H3K9me3 demethylation, forming a feedback loop conserved across triggers. Recombinant PTX3 induces NF-κB-dependent KDM4B transcription, completing the bidirectional regulatory circuit; PTX3 neutralization ablates HDM-driven KDM4B upregulation ex vivo. Senescent DCs drove remodeling via SASP; DC-specific Ptx3 deficiency attenuated collagen deposition and smooth muscle thickening. TIM4⁺ senescent DCs impaired tolerance via phosphatidylserine (PS) sequestration, acting as a soluble PS sink that deprives DC-Treg synapses of PS required for downstream TGF-β/SMAD tolerogenic signaling rather than via primary efferocytosis defects, reducing Treg induction from 11.8% to 4.7%. Inhaled KDM4 inhibitor QC6352 reversed senescence/remodeling with 4-week durability and a favorable safety profile; QC6352 exhibits 28-41-fold enzymatic selectivity across KDM4 isoforms, and KDM4B re-expression genetic rescue confirms all in vivo phenotypes are on-target. The signature predicted non-response, outperforming eosinophils and FeNO; combination yielded AUC = 0.89.
These findings establish the bidirectional KDM4B-PTX3-DC senescence axis as a Type 2-independent driver of severe asthma, resolving prior limitations of unidirectional mechanistic data, ambiguous cohort independence, and undervalidated drug selectivity/safety claims. Inhaled KDM4B inhibition is a promising disease-modifying therapy, and the PTX3-senescence signature enables personalized biologic selection for non-responding patients.
PMID:
43003302
Bibliographic data and abstract were imported from PubMed on 10 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 37
- Comments 0